Under Priority Review status, the FDA approves Otsuka Pharmaceutical Co., Ltd. (OTCPK:OTSKF) unit Astex Pharmaceuticals’ Inqovi (decitabine and cedazuridine) tablets for the treatment of adults with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Decitabine and cedazuridine are chemo agents with different mechanisms of action.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.